PM360

SEPTEMBER 21, 2023

As many in the industry now know, the Inflation Reduction Act (IRA) is the most significant reform of Medicare prescription drug coverage since the creation of Part D and has wide-ranging implications for the healthcare industry. They do not have biosimilar or generic competition available in the market.

Manufacturing 111

Manufacturing Marketing Competition Physicians 111

PM360

SEPTEMBER 21, 2023

Attention deficit hyperactivity disorder (ADHD) drug Vyvanse (lisdexamfetamine dimesylate) , manufactured by Takeda, also is facing generic competition. In the respiratory area with inhalers, it’s tough to get drugs approved, so the competition comes slowly,” he said. Starting in 2026, the provision will affect 10 Part D drugs.

Management 105

Management Manufacturing Sales Competition 105

Clarivate

OCTOBER 25, 2023

While more expensive than type 2 diabetes drugs, blood thinners follow a similar pattern of high prescription volumes. The dearth of cancer drugs (only blood cancer drug Imbruvica made this first list) stems from CMS only pursuing negotiations for Part D drugs in 2026 and 2027, then expanding to Part B drugs in 2028. With 27.5%

Prescription 52

Prescription Physicians Manufacturing Healthcare 52

Pharmaceutical Representative Training

JANUARY 29, 2025

These high prices are the result of multiple factors: theyre derived from living organisms making them sensitive and complex for both manufacturers and patients, research requires advanced technology to test for safety and effectiveness, and theyre in high demand without much competition. Starting in 2019, the US market was valued at $4.5

Marketing 52

Marketing Healthcare Healthcare Physicians 52

World of DTC Marketing

MARCH 17, 2021

Pharma has gone to court again and again to delay generic competition of biologic drugs. One company AbbVie has used the courts to stop competition of its top drug Humira. Another biologic, Enbrel, on the market since 1998, will not have its $5 billion in sales challenged until the end of 2028.

Pharma 186

Pharma Competition Prescription Sales 186

PM360

SEPTEMBER 28, 2022

In April 2022, we released an article describing proposed policies from the federal government that could impact prescription drug pricing. The facts: All Part D beneficiaries will pay $0 out of pocket for prescriptions in the catastrophic phase. On August 16, 2022, President Biden signed the Inflation Reduction Act (IRA) into law.

Manufacturing 97

Manufacturing Government Prescription Marketing 97

Clarivate

AUGUST 20, 2024

Moreover, the initial set of negotiated prices represents the first step of a process that eventually will reshape the pricing and reimbursement landscape for prescription drugs under Medicare as CMS gradually replaces private payers as the chief negotiating partner for some of the drug industry’s largest-selling treatments.

Manufacturing 52

Manufacturing Government Prescription Pharmaceutical manufacturing 52